{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:37:39Z","timestamp":1793230659605,"version":"4.5.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T00:00:00Z","timestamp":1613692800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T00:00:00Z","timestamp":1613692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1038\/s41571-021-00485-1","type":"journal-article","created":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T11:43:39Z","timestamp":1613821419000},"page":"195-196","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Will allogeneic CAR T cells for CD19+ malignancies take autologous CAR T cells \u2018off the shelf\u2019?"],"prefix":"10.1038","volume":"18","author":[{"given":"Amanda M.","family":"DiNofia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8030-7595","authenticated-orcid":false,"given":"Stephan A.","family":"Grupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,19]]},"reference":[{"key":"485_CR1","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439\u2013448 (2018).","journal-title":"N. Engl. J. Med."},{"key":"485_CR2","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531\u20132544 (2017).","journal-title":"N. Engl. J. Med."},{"key":"485_CR3","doi-asserted-by":"publisher","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","volume":"4","author":"MC Pasquini","year":"2020","unstructured":"Pasquini, M. C. et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 4, 5414\u20135424 (2020).","journal-title":"Blood Adv."},{"key":"485_CR4","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil, S., Duchateau, P., Grupp, S. A., Mufti, G. & Poirot, L. \u2018Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges. Nat. Rev. Drug Discov. 19, 185\u2013199 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"485_CR5","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1016\/S0140-6736(20)32334-5","volume":"396","author":"R Benjamin","year":"2020","unstructured":"Benjamin, R. et al. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. Lancet 396, 1885\u20131894 (2020).","journal-title":"Lancet"},{"key":"485_CR6","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaj2013","volume":"9","author":"W Qasim","year":"2017","unstructured":"Qasim, W. et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci. Transl Med. 9, eaaj2013 (2017).","journal-title":"Sci. Transl Med."},{"key":"485_CR7","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1172\/JCI24480","volume":"115","author":"L Gattinoni","year":"2005","unstructured":"Gattinoni, L. et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J. Clin. Invest. 115, 1616\u20131626 (2005).","journal-title":"J. Clin. Invest."},{"key":"485_CR8","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1097\/CJI.0b013e3181f1d644","volume":"33","author":"PC Tumeh","year":"2010","unstructured":"Tumeh, P. C. et al. The impact of ex vivo clinical grade activation protocols on human T-cell phenotype and function for the generation of genetically modified cells for adoptive cell transfer therapy. J. Immunother. 33, 759\u2013768 (2010).","journal-title":"J. Immunother."},{"key":"485_CR9","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1158\/2326-6066.CIR-17-0405","volume":"6","author":"S Ghassemi","year":"2018","unstructured":"Ghassemi, S. et al. Reducing ex vivo culture improves the antileukemic activity of chimeric antigen receptor (CAR) T cells. Cancer Immunol. Res. 6, 1100\u20131109 (2018).","journal-title":"Cancer Immunol. Res."},{"issue":"Suppl. 15","key":"485_CR10","doi-asserted-by":"publisher","first-page":"8002","DOI":"10.1200\/JCO.2020.38.15_suppl.8002","volume":"38","author":"SS Neelapu","year":"2020","unstructured":"Neelapu, S. S. et al. First-in-human data of ALLO-501 and ALLO-647 in relapsed\/refractory large B-cell or follicular lymphoma (R\/R LBCL\/FL): ALPHA study. J. Clin. Oncol. 38 (Suppl. 15), 8002 (2020).","journal-title":"J. Clin. Oncol."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41571-021-00485-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41571-021-00485-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41571-021-00485-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:44:28Z","timestamp":1684604668000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-021-00485-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,19]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["485"],"URL":"https:\/\/doi.org\/10.1038\/s41571-021-00485-1","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,19]]},"assertion":[{"value":"19 February 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.A.G. has received research support from CRISPR\/Vertex, Kite\/Gillead, Novartis and Servier, and has been a scientific advisory board or steering committee member and\/or consultant for Adaptimmune, Allogene, CBMG, Cabaletta, Cellectis, CRISPR\/Vertex, GSK, Janssen\/Johnson & Johnson, Juno, Jazz, Novartis, Roche and TCR2. A.D. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}